Brief: Zynerba Pharmaceuticals Announces Positive Long-Term Data From Phase 2 INSPIRE Trial In 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals

05/12/2022 12:37

Dec 5 (Reuters) - Zynerba Pharmaceuticals Inc  ZYNE.O :
    * ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE LONG-TERM DATA
FROM
PHASE 2 INSPIRE TRIAL IN 22Q11.2 DELETION SYNDROME AT THE ANNUAL
MEETING OF THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY
    * ZYNERBA - ZYGEL ACHIEVED STATISTICALLY SIGNIFICANT AND
CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE IN MULTIPLE
EFFICACY ASSESSMENTS
    * ZYNERBA PHARMACEUTICALS INC -  ZYGEL WAS GENERALLY
WELL-TOLERATED THROUGH 38 WEEKS OF TREATMENT

Source text for Eikon:  ID:nGNXbxj9d0 
Further company coverage:  ZYNE.O 
 ((Reuters.Briefs@thomsonreuters.com;))